Clinical trial NCT04209179: A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism
Official title: A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients With Hypoparathyroidism
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Hypoparathyroidism
Lead sponsor: Chugai Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2019-12-24
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a multi-center, placebo-controlled, randomized, double-blind, multiple-ascending dose study in patients with hypoparathyroidism.

The total duration of study medication treatment will be 13 weeks and includes a Fixed-Dose Treatment period and a Dose Titration Treatment period. The Fixed-Dose Treatment period consists of multiple daily dosing at a fixed dose level. Once patients have completed the Fixed-Dose Treatment period, patients will enter the Dose Titration Treatment period where PCO371 (or placebo), oral calcium and oral active vitamin D can each be titrated according to the patient's albumin-corrected serum calcium level.


Eligibility criteria: Inclusion Criteria:

1. Able and willing to provide written informed consent, to use the device for PRO and electronic diary and to comply with the requirements of the protocol.
2. Adult males or females ≥18 years of age
3. History of hypoparathyroidism for more than 1-year post initial diagnosis
4. PTH level is inappropriately low
5. Dose of thyroid replacement therapy must have been stable for ≥3 months prior to first dose if receiving thyroid replacement therapy
6. Receiving treatment with active vitamin D therapy (calcitriol ≥0.25 μg/day or alfacalcidol ≥0.5 μg/day)
7. Receiving Oral calcium treatment (≥1000 mg/day)
8. No significant changes in the diet from 4 weeks prior to Screening and for the duration of the study.
9. Fasting albumin-corrected serum calcium concentration between 8.0 and 9.0 mg/dL at 2 consecutive visits during the Run-In period, and no more than 25% change in daily doses of oral Ca and active vitamin D between the 2 consecutive visits during the Run-In period.
10. On Day 1, fasting albumin-corrected serum calcium level between 7.5 and 9.0 mg/dL
11. Serum magnesium level ≥ lower limit of normal and ≤ 1.2 x laboratory upper limit of normal
12. Serum 25\[OH\] vitamin D level within the laboratory normal range
13. Estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2
14. Women of childbearing potential must have a negative highly sensitive urine or serum pregnancy test result
15. For women of childbearing potential: agreement to use a highly effective contraceptive method during the treatment period and for 28 days after the last dose of study drug. Hormonal contraceptive methods must be supplemented by a barrier method (preferably male condom) and agreement to refrain from egg donation during the treatment period and for 28 days after the last dose of study drug.
16. For men: agreement to remain abstinent or use contraceptive measures. Men must refrain from donating sperm during this same period.
17. Ability to comply with the study protocol, in the investigator's judgment.
18. For Canadian sites only: Ferritin, as assessed by the local laboratory at screening, must be ≥ the lower limit of normal (LLN).

Exclusion Criteria:

1. Pregnant or breastfeeding or intending to become pregnant during the study or within 28 days after the last dose of PCO371
2. Known or suspected history of hypoparathyroidism resulting from an activating mutation in the Ca-sensing receptor gene or impaired responsiveness to PTH (pseudohypoparathyroidism)
3. Clinically significant hypomagnesemia. Adequately treated hypomagnesemia is permitted
4. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis other than hypoparathyroidism
5. History of a major bone fracture within 3 months prior to Screening
6. Any history of clinically significant bleeding disorder or clinically significant abnormal clotting times
7. History of thyroid cancer unless documented to be disease free for ≥1 year
8. History of any other cancer in the past 3 years from Screening with the exception of thyroid cancer , completely removed nonmelanoma skin cancer, basal cell skin carcinoma, and cancer in situ of the cervix
9. Dependence on monthly or more frequent parenteral calcium infusions to maintain calcium homeostasis
10. Disease processes that may adversely affect gastrointestinal absorption
11. Use of oral bisphosphonates within 6 months of Screening and/or intravenous bisphosphonate preparations within 12 months of Screening. Any use of zoledronic acid prior to Screening.
12. Use of other drugs known to influence calcium and bone metabolism such as calcitonin, fluoride tablets or cinacalcet hydrochloride within 4 weeks prior to Screening.
13. Patients who have taken inducers of CYP3A4, Pgp,or BCRP within 1 month before IMP administration or taken inhibitors of CYP3A4, P-gp, or BCRP within 2 weeks before IMP administration (or either 6 times the t1/2 of the drugs mentioned above, whichever is longer).
14. Use of loop or thiazide diuretics within 14 days prior to first dose of IMP
15. Use of anti-coagulants, anti-platelet medications, and aspirin within 2 weeks (or within 6 times the t1/2 of the drug mentioned above, whichever is longer) prior to IMP administration
16. Use of proton pump inhibitors or H2 blockers within 48 hours prior to the first dose of IMP and antacids within 4 hours prior to the first dose of IMP.
17. History of radiotherapy to the skeleton within 5 years
18. Presence of open epiphyses at the distal radius and ulna as well as carpals, metacarpals, phalanges, and pelvis
19. ALT, AST, or ALP \> 2.5 × ULN at Screening
20. Patients with documented active HBV, active HCV infection or any other known active virus infection considered to be clinically relevant by the investigator.
21. Evidence of active alcohol, drug, or other substance abuse or addiction
22. History of a seizure that is unrelated to hypocalcemia within 6 months prior to Screening
23. Insulin dependent diabetes mellitus or poorly controlled Type II diabetes mellitus (defined as hemoglobin A1c \[HbA1c\] \>8%)
24. Chronic/severe cardiac disease
25. Active gout or history of active gout within 6 months prior to first dose of study medication
26. History of clinically significant cognitive deficit that would, at the discretion of the investigator, interfere with a patient's ability to participate in the trial.
27. Any disease or condition that, in the opinion of the investigator, has a high probability of precluding the patient from completing the study or where the patient could not or would not appropriately comply with study requirements
28. Participation in any clinical trials or has taken any IMP (including placebo) either within 2 months or 5 times the t1/2 of the IMP, whichever is longer, prior to first dose of IMP for this study
29. Previous treatment with PTH-like drugs, including PTH(1-84), PTH(1-34) or other Nterminal fragments or analogs of PTH or PTH-related proteins within 2 months or 5 times the t1/2 of the treatment (whichever is longer) prior to Screening.
30. Patients with hypersensitivity to PCO371 or to any component of this drug product

Primary outcomes:
measure: Treatment-emergent adverse events
timeFrame: 13 weeks
measure: Selected adverse events
timeFrame: 13 weeks
measure: Clinically significant change in the safety parameters; vital signs
timeFrame: 13 weeks
measure: Clinically significant change in the safety parameters; body weight
timeFrame: 13 weeks
measure: Clinically significant change in the safety parameters; physical examination findings
timeFrame: 13 weeks
measure: Clinically significant change in the safety parameters; laboratory test value
timeFrame: 13 weeks
measure: Clinically significant change in the safety parameters; electrocardiogram results
timeFrame: 13 weeks
Secondary outcomes:
measure: Pharmacokinetic data of PCO371; Plasma concentrations of PCO371
timeFrame: 13 weeks
measure: Pharmacokinetic data of PCO371; AUC0-last
timeFrame: 13 weeks
measure: Pharmacokinetic data of PCO371; Cmax of PCO371
timeFrame: 13 weeks
measure: Pharmacokinetic data of PCO371; Tmax of PCO371
timeFrame: 13 weeks
measure: Pharmacokinetic data of PCO371; T1/2 of PCO371
timeFrame: 13 weeks
measure: Pharmacodynamic data in serum or plasma
timeFrame: 13 weeks
measure: Pharmacodynamic data in urine
timeFrame: 13 weeks
measure: Pharmacodynamic data; nephrogenous cAMP concentration
timeFrame: 13 weeks
measure: Pharmacodynamic data; bone turnover markers in serum or plasma
timeFrame: 13 weeks
Other outcomes:
Locations:
city: Torrance
country: United States
facility: The Lundquist Institute
state: California
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Indianapolis
country: United States
facility: Indiana University School of Medicine
state: Indiana
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Columbus
country: United States
facility: Ohio State University Wexner Medical Center
state: Ohio
city: Philadelphia
country: United States
facility: Thomas Jefferson University
state: Pennsylvania
city: Québec
country: Canada
facility: Endocrinologie et néphrologie Centre de recherche du CHU de Québec
state: CAN
city: Oakville
country: Canada
facility: McMaster University Bone Research & Education Centre
state: ONT
city: Budapest
country: Hungary
facility: Semmelweis Egyetem, Általános Orvostudományi Kar, Belgyógyászati és Onkológiai Klinika
state: HU
Study officials:
affiliation: clinical-trials@chugai-pharm.co.jp
name: Sponsor Chugai Pharmaceutical Co. Ltd
role: STUDY_DIRECTOR
References: